Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

07. Dezember 2020 10:01 ET | Quelle: Affimed N.V.

Affimed Announces Updated AFM13 Clinical Data Presentation at the American Society of Hematology Annual Meeting, Demonstrating Good Tolerability and a High Objective Response Rate in Patients with Recurrent/Refractory CD30-positive Lymphoma

AFM13 monotherapy was well tolerated and reached an Objective Response Rate of 42 percent among heavily pretreated patients with R/R CD30-positive lymphoma with cutaneous presentationImmunological...
19. November 2020 16:01 ET | Quelle: Affimed N.V.

Affimed Announces Publication of Final Study Results of its Innate Cell Engager Candidate AFM13 in Combination with MSD’s anti-PD-1 therapy KEYTRUDA® (pembrolizumab) in Blood

The phase 1b study showed a complete response (CR) rate of 46% (objective response rate [ORR] of 88%) at the recommended dose level in patients with relapsed/refractory (R/R) Hodgkin lymphoma,...
10. November 2020 06:30 ET | Quelle: Affimed N.V.

Affimed Reports Third Quarter 2020 Financial Results and Highlights Recent Operational Progress

Established license and strategic collaboration with Roivant Sciences - $60 million in upfront consideration and up to $2 billion in future milestonesRecognized milestone payment from Genentech for...
09. November 2020 16:01 ET | Quelle: Affimed N.V.

Affimed and Roivant Sciences Announce Licensing and Strategic Collaboration Agreement to Develop and Commercialize Novel Innate Cell Engagers (ICE®) for Multiple Cancer Targets

Affimed to grant license to AFM32 with options for additional ICE® molecules directed against targets not included in Affimed’s current pipeline Affimed to receive $60 million in upfront...
09. November 2020 08:20 ET | Quelle: Affimed N.V.

New Preclinical Data being Presented at SITC Underscore Promising Combinations of Affimed’s AFM13 and Cytokine-Activated Natural Killer Cells

Virtual data presentation at The Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting on Wednesday, November 11, 2020 Heidelberg, Germany, November 9, 2020 – Affimed...
05. November 2020 16:01 ET | Quelle: Affimed N.V.

Artiva Biotherapeutics and Affimed Announce Platform-to-Platform R&D Collaboration for Targeted Off-the-Shelf NK Cell Therapies

Exclusive collaboration to assess feasibility and activity of pre-manufactured, co-vialed, cryopreserved, off-the-shelf NK cell combination therapeutics targeting EGFR and additional...
04. November 2020 16:05 ET | Quelle: Affimed N.V.

Affimed Announces Presentations on its AFM13 Innate Cell Engager at the 62nd American Society of Hematology Annual Meeting and Exposition

Heidelberg, Germany, November 4, 2020 – Affimed N.V., (NASDAQ: AFMD) a clinical stage biopharmaceutical company committed to giving patients back their innate ability to fight cancer, announced today...
04. November 2020 06:30 ET | Quelle: Affimed N.V.

Affimed to Present at Upcoming Investor Conferences

Heidelberg, Germany, November 4, 2020 – Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced...
03. November 2020 06:30 ET | Quelle: Affimed N.V.

Affimed to Report 3rd Quarter 2020 Financial Results & Corporate Update November 10, 2020

Heidelberg, Germany, November 3, 2020 – Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today...
20. Oktober 2020 06:30 ET | Quelle: Affimed N.V.

Affimed and NKMax America to Study the Combination of AFM24, an EGFR-Targeted Innate Cell Engager, with SNK01 Natural Killer Cell Therapy

Proof of Concept study to establish safety and recommended dose of Affimed’s innate cell engager (ICE®) AFM24 in combination with NKMax America’s Natural Killer (NK) cells in solid...

Vorherige Seite

Nächste Seite